



MONASH
University

MONASH
PUBLIC HEALTH &
PREVENTIVE
MEDICINE

Cost-effectiveness Of Screening And Treating Children With Familial Hypercholesterolemia Early In Life From A Dutch Healthcare Perspective

Presenter: Associate Professor Zanfina Ademi, PhD

Co-authors

**Richard Norman, Jing Pang, Danny Liew, Eric Sijbrands,
Brian Ference, Gerald F Watts, and Albert Wiegman**



ISPOR, Copenhagen, 2-6th of November



This work was funded by Monash University



I have no conflict of interest to disclose



However, other researchers who were involved in this study have received grants or financial assistance from pharma companies for work not related to this study



Why familial hypercholesterolaemia (FH)?



Economic case for FH screening and treatment



Why CEA of HeFH in children?



Methods



Results



Conclusions

Why familial hypercholesterolemia?



FH is an inherited condition



Heterozygous FH (HeFH)



Homozygous FH



FH cause of premature CHD




Global issue:

a baby is born with FH every minute



Why familial hypercholesterolemia?

- Prevalence higher than previously thought
- HeFH is present in 1 per 200–250
- Of whom 20–25% are children and adolescents



2. Wiegman et. Al. European Heart Journal
(2015).36.2425-2437

Economic case for FH screening and treatment



Two aspects:



identification / diagnosis



management and primary

prevention of CVD






Contents lists available at [ScienceDirect](#)

International Journal of Cardiology

journal homepage: www.elsevier.com/locate/ijcard



Review

A systematic review of economic burden of familial hypercholesterolemia

Zanfina Ademi ^{a,*}, Gerald F. Watts ^b, A

^a Melbourne EpiCentre, Department of Medicine (RMH), University of Melbourne

Cascade screening based on genetic testing of relative index cases is cost-effective in most settings

Ann Ig 2017; 29: 464-480 doi:10.7416/ai.2017.2178

The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review

A. Rosso¹, E. Pitini¹, E. D'Andrea¹, A. Massimi¹, C. De Vito¹, C. Marzuillo¹, P. Villari¹

Genetic testing is cost-effective for implementation of cascade screening for familial hypercholesterolemia

 CrossMark

G. F. Watts, DSc, PhD, DM, FRCP, FRACP,
Jing Pang, PhD, Eric J. G. Sijbrands, MD, PhD,
Frank M. van Bockxmeer, PhD, MHGSA, FFSc (RCPA), FAHA,
Peter O'Leary, BSc, PhD, MAACB, ARCPA, FFSc (RCPA), Elizabeth Geelhoed, PhD,
Danny Liew, MBBS, FRACP, PhD

Why CEA of HeFH in children?



Contemporary evidence



Importance of early intervention



Rationale

“lower LDL-C depends on the assumption that risk in later life is determined by lifetime exposure of elevated LDL-C, rather than their LDL-C at one point”



Balance between benefits vs. risk of treatment



This research study explores the cost-effectiveness of early intervention in children with FH.



Does early intervention (at age 10) represent a cost-effective intervention relative to usual care?


1. Screening


2. Decision tree

Intervention (at age
10) with statins

Usual Care

3. Markov model





Model Assumption 1 (statin efficacy)

Variables	Braamskamp et al. 2015
LDL-C-before	6.13
LDL-C after	3.85


Model Assumption 2 (untreated cohort)

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia


Ilse K. Luijck, M.D., Albert Wiegman, M.D., Ph.D.,



For Dutch cohort, grandparents who do not receive statins was utilised




The risk of a first event is assumed to be a function of age and cumulative LDL-C.



Model Assumption 3 (effect of reduced lifetime LDL-C)




If your lifetime LDL-C is at one point lower than in the untreated arm, then your risk of first CVD event is reduced by 55%



Ference et al. 2012

Model Assumption 4 (CHD to all cause death, Simon Broome)

CHD to all cause death



Model Assumption 5 (statin perseverance and natural identification)



People identified with HeFH will continue on statins for life

- Attrition was modelled at 18.0%.



Patients not treated at a young age may begin at an older age





51% of Usual-care patients start treatment at 25 years old



Once you have an event you will be on statins

Annual Costs	Dutch data
First year cost of GP specialist visit, counselling nurse	€ 861
Average follow up year costs	€ 364
Yearly visit (80%)	€ 450
Patient on target with treatment follow-up by GP (20%)	€ 20
Cost of non-fatal MI (includes proportion of patients with PTCA and stent) plus bypass surgery	€ 15,197
Cost of CHD management	€ 683
Follow up costs once with CHD including acute admission	€ 288
Yearly costs statins Rosuvastatin and Pravastatin	€ 121.50
<i>Once off costs</i>	
Next generation sequencing (23%)	€ 1,190
Cost to detect one child through Cascade screening (77%)	€ 831
Weighted costs of screening (including cascade and next generation sequencing)	€ 914
Cost of dying in hospital	€2000


Results: Markov trace




Results: Base Case

Outputs	Undiscounted		Discounted	
Cost items €	Screened and genetically confirmed, followed by statin treatment* of affected individuals	Not screened (usual care)	Screened and genetically confirmed, followed by statin treatment* of affected individuals	Not screened (usual care)
Screening costs	1,774,844		1,774,844	
Statin use (primary prevention and monitoring)	€ 8,785,322	€ 5,966,657	€ 3,760,611	€ 2,139,311
Cost of events	€ 6,112,264	€ 5,825,938	€ 1,721,131	€ 2,007,168
Chronic costs of management	€ 10,000,480	€ 10,848,326	€ 1,404,796	€ 1,715,525
Total costs	€ 26,672,910	€ 22,640,921	€ 8,661,382	€ 5,862,005
Benefits				
Expected life years	33,886	31,599	21,003.77	19,825
Expected QALYs	28085	25,851.35	18,231.27	17,029.15
Difference in QALY gained per person			2.22	
Difference in LYG per person			2.18	
Difference in total costs per person			€ 5,172	
ICER (cost per QALY)			€ 2,330	
ICER (cost per LYG)			€ 2,372	


Results: Cost-effectiveness analysis




Results: Probabilistic Sensitivity Analysis



Results: Scenario analysis



Results: Scenario analysis





cascade screening of children followed by statin treatment of affected individuals with heterozygous FH at an age of ten years is a highly cost-effective means of delaying and preventing CHD.



our findings and conclusion are conditional on the assumptions inherent in our health economic model.



only healthcare perspective, due to limited data available



lastly, our results are important as atherosclerosis in FH starts at birth, and childhood is an important period for screening and prevention.

Thank you!

Email: zanfina.ademi@monash.edu

Twitter: @ZANFINA